No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Shanxi C&Y Pharmaceutical Group (300254.SZ): Expected net income growth of 58.76%-106.39% year-on-year in 2024.
On January 24, Gelonghui reported that Shanxi C&Y Pharmaceutical Group (300254.SZ) announced an expected net income of 40 million to 52 million yuan for 2024, representing a growth of 58.76% to 106.39% compared to the same period last year, with a non-recurring net income of 22 million to 34 million yuan. 1. The company adheres to an omnichannel marketing strategy, actively expanding new business, with a broad coverage in the Hospital, OTC, and other markets, achieving certain results, with revenue growth compared to the previous year during the reporting period. 2. In June 2023, the company signed the "Agreement on Jiang" with Li Ze Fund, Zhang Yu, and other parties.
Qianyuan Pharmaceutical: 2024 Annual Performance Forecast
Express News | Shanxi C&Y Pharmaceutical Group: Waives the right of first refusal for Jiayi Pharmaceutical.
Shanxi C&Y Pharmaceutical Group (300254.SZ): has respiratory system treatment drugs including Ambroxol Hydrochloride Dispersible Tablets and Compound Licorice Tablets.
On January 9, Gelonghui reported that Shanxi C&Y Pharmaceutical Group (300254.SZ) stated on the investor interaction platform that the company has medications for treating respiratory systems such as ambroxol hydrochloride dispersed tablets and compound licorice tablets, as well as medications for diarrhea like montmorillonite powder.
Shanxi C&Y Pharmaceutical Group (300254.SZ): Shanxi C&Y Pharmaceutical Group has been recertified as a high-tech enterprise.
On December 31, Gelonghui reported that Shanxi C&Y Pharmaceutical Group (300254.SZ) announced that its subsidiary, Zhejiang Shanxi C&Y Lisheng Pharmaceutical Co., Ltd. (referred to as "Shanxi C&Y Lisheng"), has learned from the recent announcement by the Office of the Leading Group for the Management of National High-tech Enterprise Recognition regarding the record-keeping of high-tech enterprises recognized by institutions in Zhejiang Province for 2024 that Shanxi C&Y Lisheng has passed the re-recognition as a high-tech enterprise. The certificate number is: GR202433009288, the issuance date is December 6, 2024, and the validity period is three years.
